• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Adverse Events Associated with Immune Checkpoint Blockade.

作者信息

Postow Michael A, Hellmann Matthew D

机构信息

Memorial Sloan Kettering Cancer Center, New York, NY

出版信息

N Engl J Med. 2018 Mar 22;378(12):1165. doi: 10.1056/NEJMc1801663.

DOI:10.1056/NEJMc1801663
PMID:29562154
Abstract
摘要

相似文献

1
Adverse Events Associated with Immune Checkpoint Blockade.与免疫检查点阻断相关的不良事件。
N Engl J Med. 2018 Mar 22;378(12):1165. doi: 10.1056/NEJMc1801663.
2
Adverse Events Associated with Immune Checkpoint Blockade.与免疫检查点阻断相关的不良事件。
N Engl J Med. 2018 Mar 22;378(12):1164-5. doi: 10.1056/NEJMc1801663.
3
Adverse Events Associated with Immune Checkpoint Blockade.与免疫检查点阻断相关的不良事件。
N Engl J Med. 2018 Mar 22;378(12):1163. doi: 10.1056/NEJMc1801663.
4
Adverse Events Associated with Immune Checkpoint Blockade.与免疫检查点阻断相关的不良事件。
N Engl J Med. 2018 Mar 22;378(12):1163-4. doi: 10.1056/NEJMc1801663.
5
Adverse Events Associated with Immune Checkpoint Blockade.与免疫检查点阻断相关的不良事件。
N Engl J Med. 2018 Mar 22;378(12):1164. doi: 10.1056/NEJMc1801663.
6
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.下一代免疫检查点抑制剂：黑色素瘤中的PD-1/PD-L1阻断
Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.
7
Immune checkpoint blockade: Which switches to hit and how much?免疫检查点阻断：该靶向哪些开关以及阻断到何种程度？
Immunol Lett. 2016 Dec;180:73-74. doi: 10.1016/j.imlet.2016.08.014. Epub 2016 Sep 20.
8
Myocarditis with Immune Checkpoint Blockade.免疫检查点阻断相关心肌炎
N Engl J Med. 2017 Jan 19;376(3):290-1. doi: 10.1056/NEJMc1615251.
9
Myocarditis with Immune Checkpoint Blockade.免疫检查点阻断相关心肌炎
N Engl J Med. 2017 Jan 19;376(3):291-292. doi: 10.1056/NEJMc1615251.
10
Myocarditis with Immune Checkpoint Blockade.免疫检查点阻断相关心肌炎
N Engl J Med. 2017 Jan 19;376(3):292. doi: 10.1056/NEJMc1615251.

引用本文的文献

1
Linking tumour angiogenesis and tumour immunity.将肿瘤血管生成与肿瘤免疫联系起来。
Nat Rev Immunol. 2025 Aug 14. doi: 10.1038/s41577-025-01211-z.
2
Tumor location as a risk factor for severe immune-related adverse events.肿瘤位置作为严重免疫相关不良事件的一个风险因素。
J Immunother Cancer. 2025 May 15;13(5):e011312. doi: 10.1136/jitc-2024-011312.
3
Releasing the brakes: the role of immune checkpoint inhibitors in laryngeal cancer.解除制动：免疫检查点抑制剂在喉癌中的作用
Explor Target Antitumor Ther. 2025 Feb 17;6:1002292. doi: 10.37349/etat.2025.1002292. eCollection 2025.
4
Revolutionizing head and neck squamous cell carcinoma treatment with nanomedicine in the era of immunotherapy.在免疫治疗时代，纳米医学为头颈部鳞状细胞癌的治疗带来变革。
Front Immunol. 2024 Nov 29;15:1453753. doi: 10.3389/fimmu.2024.1453753. eCollection 2024.
5
Efficacy and Safety of Pembrolizumab Monotherapy or Combined Therapy in Patients with Metastatic Triple-negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.帕博利珠单抗单药或联合治疗转移性三阴性乳腺癌患者的疗效和安全性：随机对照试验的系统评价和荟萃分析。
Curr Gene Ther. 2024;25(1):72-88. doi: 10.2174/0115665232283880240301035621.
6
Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy.预防性白细胞介素-23阻断可在双重细胞毒性T淋巴细胞相关抗原4和程序性死亡受体1免疫治疗中分离疗效与毒性。
J Immunother Cancer. 2024 Jul 31;12(7):e009345. doi: 10.1136/jitc-2024-009345.
7
Incidence of checkpoint inhibitor-associated inflammatory arthritis, immunomodulation and mortality in cancer patients on immunotherapy: a retrospective cohort study.接受免疫治疗的癌症患者中检查点抑制剂相关炎性关节炎、免疫调节及死亡率的发生率：一项回顾性队列研究
Rheumatology (Oxford). 2025 Apr 1;64(4):1637-1642. doi: 10.1093/rheumatology/keae343.
8
Efficacy and safety of immune checkpoint inhibitors in solid tumor patients combined with chronic coronary syndromes or its risk factor: a nationwide multicenter cohort study.免疫检查点抑制剂在合并慢性冠状动脉综合征或其危险因素的实体瘤患者中的疗效和安全性：一项全国多中心队列研究。
Cancer Immunol Immunother. 2024 Jun 8;73(8):159. doi: 10.1007/s00262-024-03747-w.
9
Beneficial effects of maintaining liver function during hepatic arterial infusion chemotherapy combined with tyrosine kinase and programmed cell death protein-1 inhibitors on the outcomes of patients with unresectable hepatocellular carcinoma.维持肝功能在经肝动脉灌注化疗联合酪氨酸激酶和程序性细胞死亡蛋白-1 抑制剂治疗不可切除肝细胞癌患者结局中的有益作用。
BMC Cancer. 2024 May 14;24(1):588. doi: 10.1186/s12885-024-12355-x.
10
Risk Factors for Immune Checkpoint Inhibitor-Induced Liver Injury and the Significance of Liver Biopsy.免疫检查点抑制剂所致肝损伤的危险因素及肝活检的意义
Diagnostics (Basel). 2024 Apr 14;14(8):815. doi: 10.3390/diagnostics14080815.